<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Valgimigli, Marco</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tirofiban Significantly Reduces Myocardial Damage after PCI Compared with Standard Antiplatelet Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the 3T/2R study [NCT00398463] demonstrated that the addition of tirofiban to standard therapy decreased the rate of myocardial infarction and resulted in a lower rate of major cardiovascular events 30 days after percutaneous coronary intervention compared with standard antiplatelet therapy alone in poor responders to aspirin or clopidogrel.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>